Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
Status:
Completed
Trial end date:
2012-02-22
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and effect of multiple doses of suvorexant
(MK-4305) on respiratory function in participants with chronic obstructive pulmonary disease
(COPD). This is a crossover study, so all participants will receive both suvorexant and
placebo while on study. The primary hypothesis of this study is that multiple doses of
suvorexant do not produce a clinically significant reduction of mean oxygen saturation (SaO2)
during total sleep time in participants with COPD, as compared to placebo.